Autopsy report · NCT01616225

Growth Hormone in Poor Responders to IVF Trial

“Insufficient/slow patient recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 60 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Pacific Centre for Reproductive Medicine

Sponsor type

University, hospital or other

Conditions

Infertility

Interventions

Saizen (Human Growth Hormone); Saizen (Human Growth Hormone); No Saizen Control (Standard IVF Protocol)

Participants

60 (planned, not actual)

Sites

1

Countries

Canada

Trials that died the same way

• Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
  “too slow patient recruitment” (95% match in meaning)
• A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
  “slow patient recruitment” (94% match in meaning)
• Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies
  “too slow patiënts recruitment” (93% match in meaning)
• Fesoterodine on Urgency Episodes in Parkinson's Disease Population
  “Insufficient or untimely patient recruitment” (91% match in meaning)
• Velphoro and Impact on the Oral Cavity and Gut Microbiome
  “Insufficient Patient Recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.